Vertebrobasilar thrombolysis with intravenous tirofiban: case report.
The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage. We illustrate vertebrobasilar thrombolysis with intravenous tirofiban, a selective platelet glycoprotein IIb/IIIa receptor antagonist, and discuss the potential thrombolytic properties of this class of antithrombotics.
Liebeskind
David S
DS
Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104-4283, USA. davidliebeskind@yahoo.com
Pollard
John R
JR
Schwartz
Eric D
ED
Cucchiara
Brett L
BL
McGarvey
Michael L
ML
Hurst
Robert W
RW
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000150:complications / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D020521:Stroke / Q000150:complications / Q000188:drug therapy; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D014715:Vertebrobasilar Insufficiency / Q000150:complications / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban